MCID: OVR054
MIFTS: 29

Ovarian Mucinous Neoplasm

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Mucinous Neoplasm

MalaCards integrated aliases for Ovarian Mucinous Neoplasm:

Name: Ovarian Mucinous Neoplasm 12 15
Ovarian Mucinous Tumor 12 71
Malignant Ovarian Mucinous Neoplasm 12
Malignant Ovarian Mucinous Tumor 71
Mucinous Tumor of Ovary 12

Classifications:



External Ids:

Disease Ontology 12 DOID:6067
NCIt 49 C40033 C5242
UMLS 71 C1335168 C1518233

Summaries for Ovarian Mucinous Neoplasm

Disease Ontology : 12 An ovary epithelial cancer that is characterized by the presence of mucin.

MalaCards based summary : Ovarian Mucinous Neoplasm, also known as ovarian mucinous tumor, is related to adenofibroma and ovarian brenner tumor. An important gene associated with Ovarian Mucinous Neoplasm is U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1). The drugs Paclitaxel and Oxaliplatin have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and lung.

Related Diseases for Ovarian Mucinous Neoplasm

Diseases related to Ovarian Mucinous Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 302, show less)
# Related Disease Score Top Affiliating Genes
1 adenofibroma 30.5 PAX8 KRT7
2 ovarian brenner tumor 30.5 KRT7 KRT20
3 neuroendocrine carcinoma 30.1 KRT7 KRT20 CEACAM5
4 mucinous cystadenocarcinoma 30.0 KRT7 KRT20 CEACAM5
5 polycystic liver disease 1 with or without kidney cysts 30.0 KRT7 KRT20 CEACAM5
6 mucinous adenofibroma 30.0 KRT7 CEACAM5 CDX2
7 gastrointestinal carcinoma 29.9 KRT20 CEACAM5 CDX2
8 cystadenocarcinoma 29.7 PAX8 MUC5AC KRT7 CEACAM5
9 small cell carcinoma 29.6 KRT7 KRT20 KRAS CDX2
10 cystadenoma 29.6 MUC6 MUC5AC KRT7 KRT20 CEACAM5
11 ovarian mucinous adenocarcinoma 29.4 MUC5AC KRT7 KRT20 CEACAM5 CDX2
12 mature teratoma 29.3 KRT7 KRAS CEACAM5
13 papillary adenocarcinoma 29.2 KRT7 KRAS CEACAM5 CDX2
14 carcinosarcoma 29.0 PAX8 KRT7 KRAS CEACAM5
15 adenocarcinoma 28.9 U2AF1 KRT7 KRT20 KRAS CEACAM5 CDX2
16 teratoma 28.8 KRT7 KRT20 KRAS CEACAM5 CDX2
17 krukenberg carcinoma 28.8 SATB2 PAX8 KRT7 KRT20 CEACAM5 CDX2
18 adenoma 28.8 MUC6 MUC5AC KRT7 KRT20 KRAS CDX2
19 cervical adenocarcinoma 28.8 KRT7 KRT20 KRAS CEACAM5 CDX2
20 mucinous adenocarcinoma 28.7 MUC5AC KRT7 KRT20 KRAS CEACAM5 CDX2
21 appendix adenocarcinoma 28.6 SATB2 KRT7 KRT20 KRAS CEACAM5 CDX2
22 colorectal adenocarcinoma 28.5 SATB2 KRT7 KRT20 KRAS CEACAM5 CDX2
23 pseudomyxoma peritonei 28.5 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
24 ovarian cystadenocarcinoma 28.5 PAX8 MUC6 MUC5AC KRAS CEACAM5
25 pancreatic adenocarcinoma 28.4 U2AF1 PSCA MUC6 MUC5AC KRAS CDX2
26 endometrial cancer 28.4 PAX8 KRT7 KRT20 KRAS CEACAM5 CDX2
27 cystic teratoma 28.3 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
28 villous adenoma 28.2 MUC6 MUC5AC KRT20 KRAS CEACAM5 CDX2
29 gastric adenocarcinoma 28.2 PSCA KRT7 KRT20 KRAS CEACAM5 CDX2
30 lung cancer susceptibility 3 28.0 U2AF1 MUC5AC KRT7 KRT20 KRAS CEACAM5
31 pancreatic cancer 27.6 PSCA MUC6 MUC5AC KRT7 KRT20 KRAS
32 ovarian cancer 27.5 PAX8 OCIAD2 OCIAD1 MUC5AC KRT7 KRT20
33 appendix cancer 27.4 SATB2 MUC6 MUC5AC KRT7 KRT20 KRAS
34 ovarian mucinous malignant adenofibroma 11.4
35 nephrogenic adenoma 10.5 PAX8 KRT7
36 ovary neuroendocrine neoplasm 10.5 KRT7 CDX2
37 anal canal paget's disease 10.5 KRT7 CDX2
38 adenosquamous colon carcinoma 10.5 KRT7 CDX2
39 anus adenocarcinoma 10.5 KRT7 CDX2
40 bartholin's gland carcinoma 10.4 KRT7 CDX2
41 intrahepatic bile duct adenoma 10.4 KRT7 KRT20
42 bile duct adenoma 10.4 KRT7 KRT20
43 bartholin's gland disease 10.4 KRT7 CDX2
44 atrophic vulva 10.4 KRT7 KRT20
45 rectum neuroendocrine neoplasm 10.4 KRT7 CDX2
46 small cell carcinoma of the bladder 10.4 KRT7 KRT20
47 ovarian primitive germ cell tumor 10.4 KRT7 CDX2
48 wolffian duct adenoma 10.4 PAX8 KRT7
49 bladder benign neoplasm 10.4 PAX8 KRT7
50 urinary bladder small cell neuroendocrine carcinoma 10.4 KRT7 KRT20
51 eyelid carcinoma 10.4 KRT7 KRT20
52 rete testis neoplasm 10.4 PAX8 KRT7
53 intratubular embryonal carcinoma 10.4 KRT7 KRT20
54 rete testis adenocarcinoma 10.4 PAX8 KRT7
55 papillary transitional carcinoma 10.4 KRT7 KRT20
56 meibomian cyst 10.4 KRT7 KRT20
57 urethral diverticulum 10.4 PAX8 KRT7
58 uterus perivascular epithelioid cell tumor 10.4 PAX8 KRT7
59 mucinous stomach adenocarcinoma 10.4 KRT7 CDX2
60 cystadenofibroma 10.4 PAX8 KRT7
61 papillary cystadenocarcinoma 10.4 KRT7 KRT20
62 cervical mucinous adenocarcinoma 10.4 MUC6 KRT7
63 prostate neuroendocrine neoplasm 10.4 KRT7 KRT20
64 bladder lateral wall cancer 10.4 KRT7 KRT20
65 renal adenoma 10.4 PAX8 KRT7
66 breast osteosarcoma 10.3 KRT7 KRT20
67 kidney cortex disease 10.3 U2AF1 KRT7
68 ovarian cystadenoma 10.3 KRT7 CEACAM5
69 central epithelioid sarcoma 10.3 KRT7 KRT20
70 vulvar proximal-type epithelioid sarcoma 10.3 KRT7 KRT20
71 syringoma 10.3 KRT7 CEACAM5
72 hidradenoma 10.3 KRT7 CEACAM5
73 endobronchial lipoma 10.3 MUC5AC KRT7
74 supine hypotensive syndrome 10.3 KRT7 KRT20
75 mucinous tubular and spindle renal cell carcinoma 10.3 MUC6 KRT7
76 leukoplakia of penis 10.3 KRT7 CEACAM5
77 cystic basal cell carcinoma 10.3 KRT7 KRT20
78 cystitis 10.3 KRT7 KRT20 CDX2
79 malignant acrospiroma 10.3 KRT7 CEACAM5
80 gastric tubular adenocarcinoma 10.3 MUC6 MUC5AC
81 gastric signet ring cell adenocarcinoma 10.3 KRT7 KRT20 CDX2
82 cutaneous mucoepidermoid carcinoma 10.3 KRT7 CEACAM5
83 laryngeal mucoepidermoid carcinoma 10.3 CEACAM5 CDX2
84 vulval paget's disease 10.3 KRT7 CEACAM5
85 nodular hidradenoma 10.3 KRT7 CEACAM5
86 chronic ethmoiditis 10.3 MUC6 MUC5AC
87 jejunal cancer 10.3 KRT7 KRT20 CDX2
88 jejunal adenocarcinoma 10.3 KRT7 KRT20 CDX2
89 eccrine adenocarcinoma 10.3 KRT7 CEACAM5
90 mucinous bronchioloalveolar adenocarcinoma 10.3 KRT7 KRT20 CDX2
91 external ear carcinoma 10.3 KRT7 CEACAM5
92 glandular cystitis 10.3 KRT7 KRT20 CDX2
93 vaginal adenoma 10.3 KRT7 KRT20 CDX2
94 vaginal benign neoplasm 10.3 KRT7 KRT20 CDX2
95 ovarian seromucinous carcinoma 10.3 PAX8 KRT7 CDX2
96 bladder adenocarcinoma 10.3 KRT7 KRT20 CDX2
97 adenoid basal cell carcinoma 10.3 KRT7 CEACAM5
98 horseshoe kidney 10.3 KRT7 KRT20 CDX2
99 clear cell adenocarcinoma 10.3 PAX8 KRT7 KRT20
100 retroperitoneum carcinoma 10.2 KRT7 KRT20
101 chronic cystitis 10.2 KRT7 KRT20 CDX2
102 squamous cell bile duct carcinoma 10.2 KRT7 CEACAM5
103 fibroepithelial basal cell carcinoma 10.2 KRT20 CEACAM5
104 anal canal carcinoma 10.2 KRT7 KRT20 CDX2
105 nephrogenic adenoma of urinary bladder 10.2 PAX8 KRT7 KRT20
106 anal gland adenocarcinoma 10.2 MUC5AC KRT7 CDX2
107 epididymis adenocarcinoma 10.2 PAX8 KRT7 CDX2
108 epididymis cancer 10.2 PAX8 KRT7 CDX2
109 hidrocystoma 10.2 KRT7 CEACAM5
110 bile reflux 10.2 MUC5AC CDX2
111 liver sarcoma 10.2 KRT7 CEACAM5
112 ovarian large-cell neuroendocrine carcinoma 10.2 PAX8 KRT7 KRT20
113 pericardium cancer 10.2 KRT7 CEACAM5
114 anal canal adenocarcinoma 10.2 MUC5AC KRT7 CDX2
115 nephrogenic adenoma of the urethra 10.2 PAX8 KRT7 KRT20
116 gastritis, familial giant hypertrophic 10.2 MUC6 MUC5AC
117 warthin tumor 10.2 KRT7 CEACAM5
118 eccrine acrospiroma 10.2 KRT7 CEACAM5
119 colloid carcinoma of the pancreas 10.2 PSCA MUC5AC
120 eccrine sweat gland neoplasm 10.2 KRT7 CEACAM5
121 sarcomatous intrahepatic cholangiocarcinoma 10.2 KRT7 CEACAM5
122 medulloepithelioma 10.2 KRT7 KRT20
123 collecting duct carcinoma 10.2 PAX8 KRT7 KRT20
124 eccrine porocarcinoma 10.2 KRT7 CEACAM5
125 colon leiomyosarcoma 10.2 PAX8 CEACAM5
126 eccrine papillary adenocarcinoma 10.2 KRT7 CEACAM5
127 cutaneous adenocystic carcinoma 10.2 KRT7 CEACAM5
128 ovarian mixed germ cell neoplasm 10.2 PAX8 CEACAM5
129 colon neuroendocrine neoplasm 10.2 CEACAM5 CDX2
130 chromophobe renal cell carcinoma 10.2 U2AF1 KRT7 KRT20
131 apocrine sweat gland neoplasm 10.2 KRT7 CEACAM5
132 keratinizing squamous cell carcinoma 10.2 KRT7 CEACAM5
133 jejunal neoplasm 10.2 MUC6 KRT7 KRT20
134 mediastinal cancer 10.2 KRT7 CEACAM5
135 kidney benign neoplasm 10.2 PAX8 KRT7
136 secretory meningioma 10.2 KRT7 CEACAM5
137 malignant spiradenoma 10.2 KRT7 CEACAM5
138 papillary carcinoma 10.2 PAX8 KRT7 KRT20
139 pancreatic serous cystadenoma 10.2 MUC6 CEACAM5
140 benign peritoneal mesothelioma 10.1 KRT7 CEACAM5
141 epstein-barr virus-associated gastric carcinoma 10.1 MUC6 MUC5AC
142 lymphoepithelioma-like carcinoma 10.1 KRT7 KRT20
143 acute cholangitis 10.1 MUC5AC CEACAM5
144 ovarian germ cell cancer 10.1 KRT7 CEACAM5
145 solid adenocarcinoma with mucin production 10.1 MUC6 MUC5AC KRT7
146 ureter adenocarcinoma 10.1 KRT7 CEACAM5 CDX2
147 pancreatic foamy gland adenocarcinoma 10.1 KRT7 CEACAM5 CDX2
148 anal paget's disease 10.1 KRT7 CEACAM5 CDX2
149 urethral villous adenoma 10.1 KRT7 KRT20 CEACAM5
150 pancreatic serous cystadenocarcinoma 10.1 KRT7 KRT20 CEACAM5
151 vulvar apocrine adenocarcinoma 10.1 KRT7 KRT20 CEACAM5
152 rectosigmoid junction neoplasm 10.1 KRT7 KRT20 CEACAM5
153 malignant syringoma 10.1 KRT7 KRT20 CEACAM5
154 stomach disease 10.1 MUC6 MUC5AC CDX2
155 colonic lymphangioma 10.1 KRT7 KRT20 CEACAM5
156 esophageal adenosquamous carcinoma 10.1 KRT7 CEACAM5 CDX2
157 hepatoid adenocarcinoma 10.1 KRT7 CEACAM5 CDX2
158 eccrine sweat gland cancer 10.1 KRT7 KRT20 CEACAM5
159 sweat gland cancer 10.1 KRT7 KRT20 CEACAM5
160 thymus adenocarcinoma 10.1 KRT20 CEACAM5 CDX2
161 renal pelvis adenocarcinoma 10.1 PAX8 KRT7 CEACAM5
162 adenoid squamous cell carcinoma 10.1 KRT7 KRT20 CEACAM5
163 klatskin's tumor 10.1 KRT7 CEACAM5
164 squamous papillomatosis 10.1 KRT7 KRT20 CEACAM5
165 borst-jadassohn intraepidermal carcinoma 10.1 KRT7 KRT20 CEACAM5
166 clear cell hidradenoma 10.1 PAX8 KRT7 CEACAM5
167 vulvar disease 10.1 KRT7 KRT20 CEACAM5
168 benign mesothelioma 10.1 PAX8 KRT7 CEACAM5
169 sweat gland benign neoplasm 10.1 KRT7 CEACAM5
170 bile duct mucoepidermoid carcinoma 10.1 MUC5AC KRT7 CEACAM5
171 peritoneum cancer 10.1 PAX8 KRT7 CEACAM5
172 seminal vesicle adenocarcinoma 10.0 PAX8 KRT7 KRT20 CDX2
173 apocrine adenoma 10.0 KRT7 KRAS
174 peutz-jeghers syndrome 10.0
175 fibrosarcoma 10.0
176 epulis 10.0
177 thymus clear cell carcinoma 10.0 PAX8 KRT7 KRT20 CDX2
178 thyroid angiosarcoma 10.0 PAX8 KRT20 CEACAM5
179 bladder clear cell adenocarcinoma 10.0 PAX8 KRT7 KRT20 CDX2
180 peritoneal serous adenocarcinoma 10.0 PAX8 KRT7 KRT20 CDX2
181 gallbladder benign neoplasm 10.0 KRT7 KRAS
182 ampulla of vater adenocarcinoma 10.0 MUC5AC KRT7 KRT20 CDX2
183 intrahepatic biliary papillomatosis 10.0 MUC5AC KRAS
184 colorectal cancer 1 10.0 MUC6 MUC5AC
185 cervical adenoma malignum 10.0 PAX8 MUC6 KRT7 CDX2
186 osteogenic sarcoma 10.0
187 ovarian small cell carcinoma 10.0
188 mucinous adenocarcinoma of ovary 10.0
189 struma ovarii 9.9 KRT7 KRAS
190 sarcoma 9.9
191 spindle cell sarcoma 9.9
192 pancreatic ductal carcinoma 9.9 MUC6 MUC5AC KRT7 KRT20
193 vulva adenocarcinoma 9.9 KRT7 KRT20 CEACAM5 CDX2
194 cystitis cystica 9.9 KRT7 KRT20 CEACAM5 CDX2
195 female urethral cancer 9.9 KRT7 KRT20 CEACAM5 CDX2
196 trigeminal neuralgia 9.9
197 angiosarcoma 9.9
198 ovarian disease 9.9
199 leiomyoma 9.9
200 malignant giant cell tumor 9.9
201 endometriosis 9.9
202 gastrointestinal system cancer 9.9
203 rhabdomyosarcoma 9.9
204 ovarian mucinous cystadenocarcinoma 9.9
205 malignant giant cell tumor of soft parts 9.9
206 endometrioid ovary carcinoma 9.9
207 encephalitis 9.9
208 embryonal sarcoma 9.9
209 limbic encephalitis 9.9
210 paraneoplastic neurologic disorders 9.9
211 posttransplant acute limbic encephalitis 9.9
212 linitis plastica 9.9 KRT7 KRT20 CEACAM5 CDX2
213 clear cell basal cell carcinoma 9.9 KRT7 KRT20 CEACAM5 CDX2
214 ureter, cancer of 9.9 KRT7 CEACAM5
215 nasal cavity adenocarcinoma 9.9 KRT7 KRAS CDX2
216 small cell cancer of the lung 9.9 U2AF1 KRT7 KRT20 CEACAM5
217 papilloma 9.9 KRT7 KRT20 KRAS
218 mesothelioma, malignant 9.9 KRT7 KRT20 CEACAM5
219 nasal cavity olfactory neuroblastoma 9.9 PAX8 KRT7 CEACAM5 CDX2
220 intestinal obstruction 9.9 KRT7 KRT20 CEACAM5 CDX2
221 transitional cell carcinoma 9.9 U2AF1 PSCA KRT7 KRT20
222 signet ring basal cell carcinoma 9.9 KRAS CEACAM5
223 urachal adenocarcinoma 9.9 KRAS CEACAM5
224 urethral benign neoplasm 9.9 PAX8 KRT7 KRT20 CEACAM5
225 ovarian benign neoplasm 9.9 PAX8 KRT7 KRT20 CEACAM5
226 serous cystadenocarcinoma 9.9 PAX8 KRT7 KRAS
227 nasal cavity cancer 9.9 KRT7 KRAS CDX2
228 thymic carcinoma 9.8 PAX8 KRT7 KRT20 CEACAM5
229 pancreatic mucinous cystadenoma 9.8 MUC5AC KRT7 KRT20 CEACAM5
230 wolffian duct adenocarcinoma 9.8 PAX8 KRT7 KRAS
231 immature teratoma of ovary 9.8 KRAS CEACAM5
232 paget disease, extramammary 9.8 MUC5AC KRT7 KRT20 CEACAM5
233 endosalpingiosis 9.8 PAX8 KRT7 KRAS
234 lung benign neoplasm 9.8 KRT7 KRT20 KRAS
235 bile acid synthesis defect, congenital, 5 9.8 KRAS CEACAM5
236 anus cancer 9.8 KRT7 KRAS
237 female reproductive endometrioid cancer 9.8 PAX8 KRAS
238 biliary papillomatosis 9.8 MUC6 MUC5AC KRT7 CEACAM5
239 microinvasive gastric cancer 9.7 MUC6 MUC5AC CEACAM5 CDX2
240 barrett esophagus 9.7 MUC6 MUC5AC KRT7 KRT20 CDX2
241 descending colon cancer 9.7 KRAS CEACAM5 CDX2
242 lymphangioma 9.7 KRAS CEACAM5 CDX2
243 bile duct cysts 9.7 KRT7 KRAS CEACAM5
244 papillary adenoma 9.7 KRT7 KRAS CEACAM5
245 adenosquamous carcinoma 9.7 KRT7 KRAS CEACAM5
246 rectosigmoid cancer 9.7 KRAS CEACAM5
247 ascending colon cancer 9.7 KRAS CEACAM5 CDX2
248 reproductive organ benign neoplasm 9.7 KRT7 KRAS CEACAM5
249 cecal disease 9.7 KRT7 CEACAM5
250 colonic benign neoplasm 9.7 KRAS CEACAM5 CDX2
251 benign teratoma 9.6 PAX8 KRT7 KRT20 CEACAM5 CDX2
252 bile duct adenocarcinoma 9.6 KRT7 KRAS CEACAM5
253 intestinal benign neoplasm 9.6 KRAS CEACAM5 CDX2
254 tubular adenocarcinoma 9.6 MUC5AC KRT7 KRT20 CEACAM5 CDX2
255 bladder urothelial carcinoma 9.6 U2AF1 KRT7 KRT20 KRAS
256 bile duct disease 9.6 KRT7 KRAS CEACAM5
257 gallbladder disease 9.6 KRT7 KRAS CEACAM5
258 biliary tract disease 9.6 KRT7 KRAS CEACAM5
259 wilms tumor 1 9.6 U2AF1 PAX8 KRT7 KRAS
260 uterine body mixed cancer 9.6 U2AF1 KRAS
261 rectum cancer 9.6 KRT20 KRAS CEACAM5
262 cell type benign neoplasm 9.6 KRT7 KRAS CEACAM5
263 mucinous intrahepatic cholangiocarcinoma 9.6 MUC6 MUC5AC KRT7 CEACAM5 CDX2
264 mucinous ovarian cystadenoma 9.6 SATB2 KRT7 KRT20 CEACAM5 CDX2
265 bile duct cystadenocarcinoma 9.5 MUC6 MUC5AC KRT7 KRT20 CEACAM5
266 small intestine adenocarcinoma 9.5 MUC6 MUC5AC KRAS CDX2
267 mucoepidermoid carcinoma 9.5 PAX8 MUC6 MUC5AC KRT7 CEACAM5
268 sigmoid neoplasm 9.5 KRT7 KRT20 KRAS CEACAM5
269 transverse colon cancer 9.5 KRT7 KRT20 KRAS CEACAM5
270 suppression of tumorigenicity 12 9.5 U2AF1 PSCA KRT7 KRAS
271 gastrointestinal system benign neoplasm 9.5 KRT7 KRAS CEACAM5 CDX2
272 mixed cell type cancer 9.5 PAX8 KRT7 KRAS CEACAM5
273 large cell carcinoma 9.5 KRT7 KRT20 KRAS CEACAM5
274 intrahepatic cholangiocarcinoma 9.4 MUC5AC KRT7 KRT20 KRAS CDX2
275 urinary bladder villous adenoma 9.3 MUC6 MUC5AC KRT7 KRT20 CEACAM5 CDX2
276 gastric diffuse adenocarcinoma 9.3 MUC6 MUC5AC KRT7 KRT20 CEACAM5 CDX2
277 vaginal tubulovillous adenoma 9.3 KRT7 KRT20 KRAS CEACAM5 CDX2
278 rectum adenocarcinoma 9.3 KRT7 KRT20 KRAS CEACAM5 CDX2
279 ovary epithelial cancer 9.3 U2AF1 PAX8 KRT7 KRAS CEACAM5
280 malignant ovarian surface epithelial-stromal neoplasm 9.3 U2AF1 PAX8 KRT7 KRAS CEACAM5
281 papillary serous adenocarcinoma 9.2 PAX8 KRT7 KRT20 KRAS CEACAM5
282 thyroid gland cancer 9.2 PAX8 KRT7 KRT20 KRAS CEACAM5
283 appendiceal neoplasm 9.2 SATB2 KRT7 KRAS CEACAM5 CDX2
284 biliary tract benign neoplasm 9.1 MUC6 MUC5AC KRT7 KRAS CEACAM5
285 tumor of exocrine pancreas 9.1 MUC6 MUC5AC KRAS CEACAM5 CDX2
286 endocervical carcinoma 9.1 U2AF1 PAX8 MUC6 MUC5AC KRT7 CEACAM5
287 ovarian serous cystadenocarcinoma 9.1 PAX8 MUC6 MUC5AC KRAS CEACAM5
288 cholangiocarcinoma 9.0 MUC5AC KRT7 KRT20 KRAS CEACAM5 CDX2
289 duodenum adenocarcinoma 8.9 MUC6 MUC5AC KRT7 KRAS CEACAM5 CDX2
290 duodenum cancer 8.9 MUC6 MUC5AC KRT7 KRAS CEACAM5 CDX2
291 duodenum disease 8.9 MUC6 MUC5AC KRT7 KRAS CEACAM5 CDX2
292 small intestine cancer 8.9 MUC6 MUC5AC KRT7 KRAS CEACAM5 CDX2
293 bile duct cancer 8.9 MUC6 MUC5AC KRT7 KRAS CEACAM5 CDX2
294 endocervical adenocarcinoma 8.9 U2AF1 PAX8 MUC6 MUC5AC KRT7 KRT20
295 gallbladder cancer 8.9 PSCA KRT7 KRT20 KRAS CEACAM5 CDX2
296 adenocarcinoma in situ 8.8 U2AF1 PAX8 KRT7 KRT20 KRAS CEACAM5
297 signet ring cell adenocarcinoma 8.7 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
298 ampulla of vater cancer 8.7 MUC6 MUC5AC KRT7 KRT20 KRAS CEACAM5
299 bronchiolo-alveolar adenocarcinoma 8.5 U2AF1 MUC6 MUC5AC KRT7 KRT20 KRAS
300 gastric cancer 8.5 PSCA MUC6 MUC5AC KRT20 KRAS CEACAM5
301 ovary adenocarcinoma 8.5 PAX8 MUC6 MUC5AC KRT7 KRT20 KRAS
302 appendix disease 8.4 SATB2 MUC6 MUC5AC KRT7 KRT20 KRAS

Graphical network of the top 20 diseases related to Ovarian Mucinous Neoplasm:



Diseases related to Ovarian Mucinous Neoplasm

Symptoms & Phenotypes for Ovarian Mucinous Neoplasm

Drugs & Therapeutics for Ovarian Mucinous Neoplasm

Drugs for Ovarian Mucinous Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 19, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 43805 6857599 5310940 9887054
3
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5
Bevacizumab Approved, Investigational Phase 3 216974-75-3
6 Immunoglobulins Phase 3
7 Immunologic Factors Phase 3
8 Antibodies Phase 3
9 Angiogenesis Inhibitors Phase 3
10 Mitogens Phase 3
11 Immunoglobulins, Intravenous Phase 3
12 Albumin-Bound Paclitaxel Phase 3
13 Endothelial Growth Factors Phase 3
14 Antibodies, Monoclonal Phase 3
15 Tubulin Modulators Phase 3
16 Immunoglobulin G Phase 3
17 Antimetabolites Phase 3
18 Antimitotic Agents Phase 3
19 Antineoplastic Agents, Immunological Phase 3

Interventional clinical trials:

(showing 1, show less)
# Name Status NCT ID Phase Drugs
1 A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI-Supplied Agent: Bevacizumab (NSC #704865) Compared With Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients With Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC) Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel

Search NIH Clinical Center for Ovarian Mucinous Neoplasm

Genetic Tests for Ovarian Mucinous Neoplasm

Anatomical Context for Ovarian Mucinous Neoplasm

MalaCards organs/tissues related to Ovarian Mucinous Neoplasm:

40
Ovary, Endothelial, Lung, Colon, Uterus, Appendix

Publications for Ovarian Mucinous Neoplasm

Articles related to Ovarian Mucinous Neoplasm:

(showing 56, show less)
# Title Authors PMID Year
1
Primary signet ring cell carcinoma with neuroendocrine differentiation arising in mucinous borderline tumor of the ovary. 61
31872017 2020
2
A rare case of a primary retroperitoneal mucinous cystic tumour with borderline malignancy and literature review. 61
31488447 2019
3
Preoperative Optimization and Choreographed Physiological Evaluation for Resection of Giant Abdominal Neoplasm: A Case Report. 61
31021824 2019
4
Ovarian mucinous cystic tumor associated with sarcomatous mural nodule and benign Brenner tumor: A case report and literature review. 61
30653119 2019
5
Clinicopathological Characteristics of Ovarian Metastasis from Colorectal and Pancreatobiliary Carcinomas Mimicking Primary Ovarian Mucinous Tumor. 61
30194204 2018
6
Improvement of hyperandrogenism, oligo-ovulation, and ovarian morphology in a patient with polycystic ovary syndrome: possible role of ovarian wedge resection. 61
29298536 2018
7
Mucinous Carcinomatosis: A Rare Association between an Ovarian Tumor and an E-GIST. 61
29593930 2018
8
A case report of an incidental Brenner tumor found after resection of a large ovarian mucinous neoplasm. 61
29960208 2018
9
Giant mucinous ovarian borderline tumor. A good lesson from an asymptomatic case. 61
30071377 2018
10
Dual Immunostain With SATB2 and CK20 Differentiates Appendiceal Mucinous Neoplasms From Ovarian Mucinous Neoplasms. 61
28340228 2017
11
A Pyloric Gland-Phenotype Ovarian Mucinous Tumor Resembling Lobular Endocervical Glandular Hyperplasia in a Patient with Peutz-Jeghers Syndrome. 61
27550049 2017
12
Angiosarcoma Arising in Ovarian Mucinous Tumor: A Challenge in Intraoperative Frozen Section Diagnosis. 61
27872782 2016
13
Osteosarcoma as Malignant Mural Nodule in Ovarian Mucinous Neoplasms of Intestinal Type: Report of 2 Cases. 61
25760909 2015
14
Coexistence of mature cystic teratoma and adenocarcinoma in situ within atypical proliferative mucinous tumour of ovary--a case report of 35-year-old woman. 61
26050362 2015
15
Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision? 61
25473748 2015
16
Mucinous borderline ovarian tumor with ascites. 61
25518783 2014
17
Unique features and insights from mucinous tumors of ovary in childhood: clinicopathological study of 15 cases including four premenarchal cases. 61
24575832 2014
18
An evaluation of the morphologic features of low-grade mucinous neoplasms of the appendix metastatic in the ovary, and comparison with primary ovarian mucinous tumors. 61
24300528 2014
19
Follistatin is a novel biomarker for lung adenocarcinoma in humans. 61
25347573 2014
20
Multiple genital tract tumors and mucinous adenocarcinoma of colon in a woman with Peutz-Jeghers syndrome: a case report and review of literatures. 61
25120832 2014
21
Trigeminal neuralgia as the first clinical manifestation of anti-hu paraneoplastic syndrome induced by a borderline ovarian mucinous tumor. 61
24575026 2014
22
Association of pancreatic adenocarcinoma up-regulated factor expression in ovarian mucinous adenocarcinoma with poor prognosis. 61
25197383 2014
23
Is routine appendectomy at the time of primary surgery for mucinous ovarian neoplasms beneficial? 61
23835504 2013
24
Increased expression of OCIA domain containing 2 during stepwise progression of ovarian mucinous tumor. 61
22726067 2012
25
Low-grade appendiceal mucinous neoplasm with disseminated peritoneal adenomucinosis involving the uterus, mimicking primary mucinous endometrial adenocarcinoma: a case report. 61
21733040 2011
26
Borderline ovarian mucinous neoplasm recurring as small cell carcinoma of hypercalcemic type: evidence for an epithelial histogenesis and relationship with ovarian mucinous tumors for this enigmatic neoplasm. 61
21623206 2011
27
Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. 61
20154039 2010
28
Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. 61
18665037 2008
29
Primary ovarian mucinous tumors with signet ring cells: report of 3 cases with discussion of so-called primary Krukenberg tumor. 61
18670351 2008
30
Nuclear morphometry and AgNOR quantification: computerized image analysis on ovarian mucinous tumor imprints. 61
18630841 2008
31
A huge ovarian mucinous cystadenoma in a 14-year-old premenarchal girl: review on ovarian mucinous tumor in premenarchal girls. 61
18312801 2008
32
Ovarian mucinous tumor arising in mature cystic teratoma associated with pseudomyxoma peritonei: a case with possible respiratory epithelial differentiation. 61
18156973 2008
33
Malignant or borderline mucinous cystic neoplasms have a larger number of loculi than mucinous cystadenoma: a retrospective study with MR. 61
17659568 2007
34
Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. 61
17527072 2007
35
Establishment and characterization of a human ovarian sarcomatoid carcinoma cell line BUPH:OVSC. 61
16174236 2005
36
Metastatic duodenal carcinoma simulating primary mucinous tumor of the ovary. 61
15300447 2005
37
Metastasis of small cell carcinoma of lung into an ovarian mucinous neoplasm: immunohistochemistry as a useful ancillary technique for diagnosis and classification of rare tumors. 61
15722802 2005
38
Mucinous tumors of the ovary: a review. 61
15626914 2005
39
Mucinous borderline ovarian tumors: points of general agreement and persistent controversies regarding nomenclature, diagnostic criteria, and behavior. 61
15297962 2004
40
[Pseudomyxoma peritonei: report of 11 cases with a literature review]. 61
12622904 2002
41
Heterogeneous genetic alterations in ovarian mucinous tumors: application and usefulness of laser capture microdissection. 61
11727259 2001
42
WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. 61
11488072 2001
43
A rare case of pseudomyxoma peritonei presenting an unusual inguinal hernia and splenic metastasis. 61
11446896 2001
44
Mucinous cystadenoma coexisting with stromal tumor with minor sex-cord elements of the ovary: a case report. 61
11306755 2001
45
[Peritoneal pseudomyxoma associated with an ovarian and appendicular mucinous tumor]. 61
10089686 1999
46
[Ovarian mucinous tumor of gastric and intestinal type associated with Peutz-Jeghers syndrome: in situ hybridization study of apomucin gene transcripts]. 61
10051919 1998
47
Anaplastic nodules in an ovarian mucinous tumor. Case report and literature review. 61
10215434 1998
48
Identical, unique p53 mutations in a primary ovarian mucinous adenocarcinoma and a synchronous contralateral ovarian mucinous tumor of low malignant potential suggest a common clonal origin. 61
9158713 1997
49
Neuroendocrine carcinoma arising in an ovarian mucinous cystadenoma. 61
8786207 1996
50
Fibrosarcoma arising in an ovarian mucinous tumor: a case report. 61
11578409 1994
51
Rhabdomyosarcoma coexistent with ovarian mucinous cystadenocarcinoma: a case report. 61
1563909 1992
52
Ovarian mucinous tumor with mural nodules of anaplastic carcinoma. 61
2477315 1989
53
Immunohistology of a sarcomatous mural nodule in an ovarian mucinous cystadenocarcinoma. 61
3429109 1987
54
Distribution of GICA in normal gastrointestinal and endocervical mucosae and in mucinous ovarian cysts using antibody NS 19-9. 61
3511671 1986
55
Ovarian mucinous cystadenocarcinoma with mural nodule of carcinomatous derivation. A light and electron microscopic study. 61
6821801 1983
56
Mucinous ovarian tumors with giant cell mural nodules. A report of two cases. 61
6276116 1981

Variations for Ovarian Mucinous Neoplasm

Expression for Ovarian Mucinous Neoplasm

Search GEO for disease gene expression data for Ovarian Mucinous Neoplasm.

Pathways for Ovarian Mucinous Neoplasm

GO Terms for Ovarian Mucinous Neoplasm

Biological processes related to Ovarian Mucinous Neoplasm according to GeneCards Suite gene sharing:

(showing 1, show less)
# Name GO ID Score Top Affiliating Genes
1 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.8 KRAS MUC5AC MUC6

Sources for Ovarian Mucinous Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....